The National Security Agency’s ability to capture Internet traffic on United States soil has been based on an extraordinary, decades long partnership with a single company: AT&T.
THE NATIONAL SECURITY AGENCY’S ability to spy on vast quantities of Internet traffic passing through the United States has relied on its extraordinary, decades-long partnership with a single company: the telecom giant AT&T.
While it has been long known that American telecommunications companies worked closely with the spy agency, newly disclosed NSA documents show that the relationship with AT&T has been considered unique and especially productive. One document described it as “highly collaborative,” while another lauded the company’s “extreme willingness to help.”
AT&T’s cooperation has involved a broad range of classified activities, according to the documents, which date from 2003 to 2013. AT&T has given the NSA access, through several methods covered under different legal rules, to billions of emails as they have flowed across its domestic networks. It provided technical assistance in carrying out a secret court order permitting the wiretapping of all Internet communications at the United Nations headquarters, a customer of AT&T.
The same drug that Rush Limbaugh was taking….Very scary…
As of Thursday, Aug. 13, the Food and Drug Administration has approved the limited use of OxyContin in pediatric patients between the ages of 11 and 16. The decision was made after a study was conducted by manufacturers of OxyContin, Purdue Pharma in Stamford, Conn., and the FDA assures that use will be tightly monitored and informed by the evidence of this research.
OxyContin, an extended-release version of the common opioid medication, oxycodone has gained an infamous reputation as a highly abused narcotic. Used to treat patients with severe pain, OxyContin is said to trigger the same systems in the brain as heroin, making it just as addictive. While many are finding it hard to believe that the FDA would allow such a drug for children, the administration’s Dr. Sharon Hertz, director of anesthesia and analgesia, gave a talk at the Center for Drug Evaluation and Research detailing just what OxyContin use for pediatric patients would look like.
Promontory Financial Group built a reputation as one of the financial industry’s most powerful consultants by steering banks through potentially damaging clashes with regulators. Now, it is preparing for a confrontation of its own.
In an unusual legal battle set to begin this week, Promontory plans to challenge the move by New York’s state banking regulator to block the consulting firm from advising New York-based banks in some cases, according to documents reviewed by The Wall Street Journal and people familiar with the matter.
New York’s Department of Financial Services took that step after saying that Promontory watered down reports about potential sanctions violations by Standard Chartered PLC.